Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Lantheus ( (LNTH) ) is now available.
Lantheus Holdings, Inc. announced the appointment of Phuong Khanh (P.K.) Morrow, M.D., to its Board of Directors, effective February 1, 2025. Dr. Morrow, a seasoned pharmaceutical executive with extensive oncology expertise, will serve as an independent director and a member of the Science and Technology Committee. Her appointment comes during a period of growth for Lantheus, as it aims to enhance its strategic initiatives and innovative efforts in radiopharmaceuticals. Dr. Morrow’s experience is expected to bolster the company’s research and development capabilities, aligning with its vision to improve patient outcomes.
More about Lantheus
Lantheus is a leading radiopharmaceutical-focused company dedicated to providing innovative solutions that enable clinicians to find, fight, and follow disease for better patient outcomes. With over 65 years of experience, the company is headquartered in Massachusetts and has offices in Canada and Sweden.
YTD Price Performance: 4.20%
Average Trading Volume: 1,107,896
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $6.34B
See more insights into LNTH stock on TipRanks’ Stock Analysis page.
